Citations

Clear

287 citation(s) found for "O'Shea, C".

Tips and Tactics for Successful Arthrocentesis
Haug, Logan , French, Robert J, Melville, David M , Flug, Jonathan A , Stanborough, Rupert, Long, Jeremiah

Mayo Clinic

RadioGraphics | October 22, 2026 | Volume: 46 | Issue: 11 | Pages: No page available

10.1148/rg.260063 | PMID 42911847 Get It

Arthrocentesis is a fundamental diagnostic and therapeutic procedure performed by radiology trainees, general radiologists, and musculoskeletal radiologists, and procedural success depends on careful preprocedural planning, appropriate tool selection, and knowledge of joint-specific approaches.
Congruent‐Arc Posterior Distal Tibial Allograft Shows Greater Radiographic Glenoid Concavity Compared With Traditional Lateral Tibial Allograft in Glenoid Bone Loss
Tummala, Sailesh V , Lai, Cara H , Tarabichi, Saad , Flug, Jonathan A

Mayo Clinic

Arthroscopy | October 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/arj.70610 | PMID 42870499 Get It

Purpose To compare radiographically the concavity depth and slope angle of the congruent‐arc distal tibial allograft (CA‐DTA), harvested from the posterior distal tibia, with the traditional lateral distal tibial allograft (traditional DTA) used for glenoid reconstruction in anterior shoulder instability with bone loss. Methods A convenience sample of 32 ankle computed tomography scans from patients ≤35 years old without prior trauma, arthritis, or ankle pathology were retrospectively reviewed. Using standardized coronal (traditional DTA) and sagittal (CA‐DTA) reconstructions, 2 independent reviewers measured allograft concavity depth (mm) and slope angle. Paired t tests compared traditional versus CA‐DTA measurements. Intraclass correlation coefficients assessed reliability. Significance was set at P < .05. Results The mean age of patients was 25.2 years, with 50% (n = 18) of patients being male. Compared with the traditional DTA, the CA‐DTA showed significantly greater glenoid concavity change (2.9 ± 0.65 mm vs −2.3 ± 0.71 mm; P < .001) and slope angle (22.9°± 4.02 vs −9.78°± 4.07; P < .001). All CA‐DTAs showed positive concavity and slope, whereas all traditional DTAs produced negative values. Conclusions The CA‐DTA consistently increased both concavity and slope, whereas the traditional DTA decreased these measures. By leveraging the posterior tibial surface, the CA‐DTA more reliably recreates the anatomic “half‐pipe” glenoid contour that contributes to bony concavity‐compression‐based stability. Clinical Relevance The CA‐DTA offers a graft alternative that more reliably restores glenoid concavity in anterior shoulder instability with glenoid bone loss. This has potential implications for improved glenohumeral stability and clinical outcomes.
Longitudinal Data from a Large, Multi-Target Stool DNA Colorectal Cancer Screening Program
Garg, Sushil Kumar , Hintz, Carley F , Kolarik, Hannah J , Mau, Brayden , Hubers, Jeffrey , Arce, Victor, Ebner, Derek W. , Gurudu, Suryakanth, Bi, Yan , Greenwood, Jason D. , Chaudhary, Rajeev, Hubers, Jeffery , Gurudu, Suryakanth R, Greenwood, Jason , Kisiel, John B , Ebner, Derek , Kolarik, Hannah , Arce, Victor, Kisiel, John B.

Mayo Clinic

American Journal of Gastroenterology | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004196 | PMID 42690929 Get It

Background & Aims: Multi-target stool DNA (mt-sDNA) is an established stool-based colorectal cancer screening test, yet long-term performance is not well-described. We evaluated follow-up colonoscopy rates & quality, neoplasia yield, and repeat-testing adherence over 10 years with an integrated screening program. Methods: We assembled a retrospective cohort of mt-sDNA tests (September 2014–July 2025) within a multi-site health system. A validated large-language-model pipeline extracted colonoscopy, pathology, and quality endpoints from free-text reports. Detection outcomes (adenoma detection rate, advanced neoplasia, modified advanced adenoma, sessile serrated lesion (SSL), and negative exams) were calculated among high-quality exams; adenocarcinoma, bowel preparation adequacy, and cecal intubation rate (CIR) used all screening exams. We assessed colonoscopy completion ≤1 year after positive mt-sDNA, follow-up colonoscopy findings, findings by time-to-colonoscopy, and adherence to repeat mt-sDNA after negative result. Results: Among 148,624 tests in 110,410 individuals, positivity was 13.6%. Of 19,506 positives, 65.1% completed colonoscopy within 12 months (median 82 days). Colonoscopy after a positive mt-sDNA had high yield: advanced adenoma diagnosis was 30.7%; adenocarcinoma was 1.3%. Of patients who had colonoscopy within 3 years of a negative mt-sDNA test, 45.2% had adenoma/serrated lesion, 9.3% had advanced adenoma and 0.5% had colon cancer. Adenoma detection rate after positive mt-sDNA (>50%) exceeded specialty society quality benchmarks and increased over time; Longer intervals (>6 months) to colonoscopy after a positive test were associated with higher advanced adenoma (trend P=0.001).After an initial negative mt-sDNA, only 35.3% were screened again by mt-sDNA testing within 3 years. Conclusions: Over a decade,mt-sDNA screening achieved high colonoscopy qualitybut revealed critical gaps in the care cascade. One-third of positive tests lacked timely follow-up and nearly two-thirds of negative tests were not repeated on schedule, suggesting opportunities for system-level interventions.
Cold and Room-Temperature Platelets in Cardiac Surgery
Spinella, Philip C., Zantek, Nicole D., Nicolson, Susan C., Khanna, Ashish K., Boisen, Michael L., Williams, Tiffany M. , Monteleone, Matthew, Pavey, Warren, Smith, Bradford B., Ahmed, M. Iqbal, Jeng, Eric, Flynn, B S, Joshi, Ravi V. , Preuss, James , Goswami, Dheeraj, Lewis, Choy, Tint, Hlaing , Kwak, Jenny , Sodha, Neel, Simon, Eric R. , Van, Philbert Y., Greilich, Philip E. , Booth, Frank V. McL., Carter, Camille, Keegan, Anastazia , Cap, Andrew P., Matuk, James, McGlothlin, Anna, Berry, Nicholas , Lewis, Roger , Steiner, Marie E., Group, CHIPS Investigator, Hu, Paula, Hawkins, Jaleah, Jobes, David R. , Fadeyi, Emmanuel A. , Reynolds, Abigail M.A., Bell, Carter G., Gandhi, Manish J., Montonye, Beth, Serna-Gallegos, Derek, Sultan, Ibrahim, Kinney, Stephanie , Molony, Kathleen, Hensch, Lisa, Resheidat, Ashraf, Malivers, Martine, Hahn, Rebbecca, Viellez, Annette Le, Pepperell, Dominic , Lu, Qun, Downey, Frank, Haeger, Kayla N., Baltagi, Sirine , Jaquiss, Robert D.B., Noland, Daniel K., Cole, Regina, Duffin, Aspen, Scott, John P., Zeng, Long, Ballew, Angie, Webb, Christopher, Jessen, Michael, Hopson, Erryn, Mickle, Peri, Kavanagh, Simon, Matzelle, Shannon, Mennie, Colleen, Davenport, Robertson, Chlebeck, Therese, Zenk, Emmy, Lotz, Daniel T., Choi, Warren , Hobbs, Rhonda, Baptise, Amanda, DeChristopher, Phillip, Schoenecker, Nancy, Rodheim, Dianna, Connor, Joseph, Griese, Daniel J., McGuire, Erin, VanSandt, Mandy, Sera, Valerie, O’Donovan, Justine , Marks, Denese, Johnson, Lacey, Viele, Kert , Cholette, Jill M., Selke, Frank, Silverman, Toby, Shea, Susan, Yazer, Mark, Young, P. J., Ness, Paul Van, Dean, J. Michael, Shaz, Beth, Stubbs, James, Klompas, Allan M. , Spinella, Philip C. , Zantek, Nicole D. , VanBuren, John M. , Nicolson, Susan Craig , Khanna, Ashish K. , Boisen, Michael L , Monteleone, Matthew P., Bashir, Dalia A. , Pavey, Warren , Niebler, Robert A. , Jeng, Eric I-Hun , Goswami, Dheeraj , Yamada, Chisa , Lewis, Choy R., Cohn, Claudia S. , Sodha, Neel R. , Cap, Andrew , Matuk, James , Smith, Mark M. , Montonye, Beth L., Kaplan, Alesia , Kinney, Stephanie , Resheidat, Ashraf M., Downey, Francis X. , Ballew, Angie , Matzelle, Shannon A, Crowe, Liz , DeChristopher, Phillip J., Griese, Daniel, Sera, Valerie, Marks, Denese C. , Johnson, Lacey , Cholette, Jill M., Levy, Jerrold H. , Silverman, Toby , Yazer, Mark H. , Strandenes, Geir , Shaz, Beth H. , Stubbs, James R.

Mayo Clinic

JAMA | August 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13328 | PMID 42606886 Get It

Importance Patients undergoing cardiac surgery with cardiopulmonary bypass often require platelet transfusions for bleeding. Platelets are routinely stored at room temperature (20-24 °C) for up to 5 to 7 days; however, cold storage (1-6 °C) may allow for increased storage duration without loss of hemostatic function. Objective To determine the maximum cold-storage duration, up to 21 days, for which cold-stored platelets (CSPs) are noninferior or superior in hemostatic efficacy to room-temperature platelets (RTPs) when transfused in actively bleeding patients undergoing cardiac surgery with cardiopulmonary bypass. Design, Setting, and Participants A phase 3, multicenter, randomized, partially blinded, adaptive, noninferiority, storage duration–ranging trial conducted in pediatric and adult patients undergoing cardiac surgery with planned cardiopulmonary bypass at 27 sites in the US and Australia from December 2021 to March 2025. Statistical analysis was conducted from September 9 to October 3, 2025. Intervention Patients were randomized 2:1 to receive CSPs with a maximum of 21 days of storage vs RTPs with a maximum of 7 days of storage. Main Outcomes and Measures The primary outcome was a hemostatic efficacy score with values ranging from 1 to 5 and higher values indicating greater bleeding. The noninferiority margin was 1 point. The success criterion was met if at least 1 cold-storage duration of 7 days or more had a posterior probability of noninferiority of at least 97.5%. The secondary outcome was 24-hour chest tube output. Results Of the 1000 patients who underwent platelet transfusion, 989 were included in the primary analysis (650 CSPs and 339 RTPs). The cohort had a mean (SD) age of 42.1 (30.1) years and 67.8% were male. CSPs were noninferior to RTPs for the primary outcome, with a probability of greater than 99.9% for all cold-storage durations. Pooled across storage durations, CSPs had a mean difference from RTPs of 0.09 (95% credible interval, −0.06 to 0.23). Median (IQR) chest tube output at 24 hours (8.9 mL/kg [5.2-15.4] for CSPs vs 8.4 mL/kg [5.5-15.9] for RTPs; difference in medians, 0.4 [95% CI, −1.0 to 1.5]) was not statistically different between study groups. In a post hoc analysis, as all storage durations were noninferior, considering the CSPs as a single group, the hemostatic efficacy score was similar between both groups: mean (SD) of 3.08 (1.15) CSPs vs 2.99 (1.10) RTPs. There were no differences in venous or arterial thrombotic events, transfusion-associated adverse events, acute respiratory distress syndrome, kidney failure, septic shock, and mortality between the study groups, except for increased reexploration rates in the CSP group. Conclusions and Relevance For patients undergoing cardiac surgery, CSPs stored up to 21 days are noninferior to RTPs for the control of active surgical bleeding. Use of CSPs may allow for increased availability of platelets by reducing wastage and shortages and may allow for incorporation of platelets into inventory at locations where platelets cannot be maintained due to the 5- to 7-day shelf life of RTPs. Trial Registration ClinicalTrials.gov Identifier: NCT04834414
Most of moderate to severe ulcerative colitis patients in academic clinical practice still do not qualify for randomized controlled trials
Elmasry, Sandra, Pasha, Shabana, Kaur, Manreet , Leighton, Jonathan A. , Gurudu, Suryakanth, Ha, Christina , Elmasry, Sandra , Gurudu, Suryakanth R, Ha, Christina , Pasha, Shabana F.

Mayo Clinic

Crohn’s & Colitis 360 | August 4, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/crocol/otag092 | PMID 42633268 Get It

Abstract Background While biologic and small molecule therapies have expanded treatment options for moderate to severe ulcerative colitis (UC), prior research revealed that only 26% of patients in routine practice would have qualified for pivotal randomized controlled trials (RCTs) due to stringent eligibility criteria. This study aimed to evaluate contemporary clinical trial eligibility for UC patients in a tertiary care setting based on more recently approved therapies. Methods We performed a retrospective cohort study of adult patients with moderate to severe UC (total Mayo score ≥6) seen between January 2022 and February 2023. Inclusion and exclusion criteria from seven phase III RCTs conducted between 2012 and 2022 (eg, VARSITY, UNIFI, OCTAVE, LUCENT) were applied to determine patient eligibility and identify reasons for ineligibility. Results Of 150 patients (mean age 44.9 years; 55.7% male), only 42.7% were eligible for at least one RCT. The most common exclusion factor was current or prior medication use, followed by anemia, dysplasia, and disease extent. Trial eligibility did not significantly differ by age, gender, or disease duration. Conclusions Despite modest improvements since 2012, over half of real-world UC patients remain ineligible for current RCTs. Expanding inclusion criteria, especially regarding prior medication exposure, and adopting more inclusive trial designs may enhance external validity. Addressing disparities in trial access and participation remains essential to ensuring equitable representation and improving clinical applicability of RCT findings.
C71-16 Diagnostic Accuracy of Genomic Classifier in Patients With Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Studies Published up to 2025
Singh, A, Singh, A, Jena, A, Phadke, R, Paudel, E O’Shea, PAUDEL, ERIN E O'SHEA

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2784 Get It

Abstract Rationale The diagnosis of interstitial lung disease (ILD) requires a multidisciplinary discussion (MDD), in which high-resolution computed tomography (HRCT) and histopathology play key roles. Genomic classifiers have recently been introduced for clinical use, in which lung tissue obtained via transbronchial forceps biopsy undergoes whole-transcriptome RNA sequencing followed by gene expression analysis. These molecular tools are particularly valuable in establishing a diagnosis of idiopathic pulmonary fibrosis (IPF) in patients without a definite usual interstitial pneumonia (UIP) pattern on imaging. Although genomic classifiers are increasingly utilized in clinical practice, data on their diagnostic performance continue to evolve, warranting an updated analysis of the current evidence. Methods A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Comprehensive search of PubMed, MEDLINE, Embase, Scopus and the Cochrane Library were performed through October 2025 using predefined terms including “genomic classifier,” “Envisia,” “UIP,” and “interstitial lung disease.” Eligible studies were which enrolled adult patients with ILD of uncertain etiology in whom genomic classifiers were compared with histopathologic or MDD based reference standards. True positive, false positive, false negative, and true negative data were extracted to calculate pooled estimates of sensitivity, specificity and the area under the receiver-operating characteristic curve (AUROC) using a random-effects bivariate model. Results Six studies comprising 347 patients met inclusion criteria, with sample sizes ranging from 24 to 98 participants. Across studies, sensitivity ranged from 59% to 85% and specificity from 75% to 100%. The pooled sensitivity was 68% (95% CI, 60-76%; P &lt; 0.001) and specificity 77% (95% CI, 70-85%; P &lt; 0.001), with an estimated AUROC of 0.73 (95% CI, 0.65-0.81) indicating discriminative performance. In two studies evaluating clinical impact, incorporation of genomic classifier data into MDD increased diagnostic confidence in ILD subtyping by 30-50%. No major adverse events related to transbronchial tissue acquisition were reported. Conclusions Genomic classifiers represent a promising, less invasive adjunct for identifying UIP patterns in ILD, demonstrating good overall diagnostic accuracy. Incorporating classifier results within MDD frameworks enhances diagnostic confidence and may reduce the need for surgical lung biopsy in appropriately selected patients. However, small study sizes, potential funding bias and limited accessibility highlight the need for larger, independently conducted prospective studies to further define their role in future IPF diagnostic algorithms. This abstract is funded by: None
Effects of Coping Resources on Depressive Symptoms in Rural Heart Failure Patient-Caregiver Dyads: An Actor-Partner Interdependence Modeling Analysis
Graven, Lucinda J. , Stearns, Erin, Ledermann, Thomas , Plummer, Shea, Hubble, Marlee, Howren, M. Bryant, Howren, Matthew Bryant , Grant, Joan S. , Abbott, Laurie S.

Mayo Clinic

Journal of Family Nursing | May 11, 2026 | Volume: 32 | Issue: 3 | Pages: 147-158

10.1177/10748407261440167 | PMID 42109052 Get It

Background: Managing heart failure (HF) can be challenging for rural dyads, potentially contributing to depressive symptoms. Coping resources may be important components for dyadic interventions targeting depressive symptoms. Purpose: To explore actor and partner effects of coping resources on depressive symptoms in rural HF dyads. Methods: Using a cross-sectional design, data were collected from 42 rural HF dyads using the Interpersonal Support Evaluation List-12, Social Problem-Solving Inventory Revised-Short, Global Family Function, Family APGAR, and the Center for Epidemiological Studies-Depression scales. Data were analyzed using the Actor-Partner Interdependence Model. Results: Patients were 66.42 and caregivers were 60.83 years old. No partner effects noted. Significant actor effects for patients and caregivers between their own social support and depressive symptoms and their own problem-solving and depressive symptoms were found. There was also a significant actor effect between the caregivers’ family satisfaction and depressive symptoms. Conclusions: Dyadic interventions that enhance coping resources are needed.
An APOE *4-Informed Genomic Atlas of the X Chromosome in Alzheimer’s Disease
Cook, Noah , Zeng, Youjie , Yang, Chenyu , Jiang, Zhiwen , Wang, Ting‐Chen , Guen, Yann Le , Cody, Karly Alex , Johnson, Matthew, Zhang, Rui, Merritt, Victoria C. , Hauger, Richard L. , Program, the VA Million Veteran, FinnGen, Koran, Mary Ellen, Mormino, Elizabeth C. , Gordon, Brian , DeCasien, Alex, Andrews, Shea J. , Logue, Mark, Greicius, Michael D. , Le Guen, Yann , Cody, Karly A , Koran, Mary Ellen , Gordon, Brian A , Andrews, Shea , Dumitrescu, Logan , Archer, Derek , Seto, Mabel , Pottier, Cyril , Cruchaga, Carlos , Sherva, Richard , Logue, Mark W. , Napolioni, Valerio , Belloy, Michael E , Cook, Noah , Zeng, Youjie , Yang, Chenyu , Zhang, Rui, Merritt, Victoria C. , Hauger, Richard L. , Koran, Mary Ellen I. , Mormino, Elizabeth C. , DeCasien, Alex R. , Dumitrescu, Logan , Archer, Derek B. , Hohman, Timothy J. , Belloy, Michaël E.

Mayo Clinic

No container title available | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.05.26352461 | PMID 42145643 Get It

Abstract The genetic contributions of the X chromosome to Alzheimer’s disease (AD) remain poorly understood yet are expected to importantly shape sex differences in AD. We therefore performed large-scale X-chromosome-wide association studies (N=1,240,451), evaluating differential risk due to sex, APOE *4, and escape from X-chromosome inactivation, finding most X-linked loci appear relevant to female-biased AD etiology. In evaluating genetic pleiotropy with hormonal, lipid, and brain imaging traits, we discovered X-linked AD loci converged on white matter traits, particularly in the anterior corona radiata and splenium of the corpus callosum. Through brain-centric functional genomics analyses, we then nominated candidate causal genes, including 5 that appeared highly robust. Notably, we found the escape gene RBBP7 decreases AD risk in APOE *4 carriers likely through higher expression in excitatory neurons to counter tau-related neurodegeneration. Altogether, we provide an atlas of sex and APOE *4-informed candidate X-linked AD risk loci, genes, and mechanisms that will guide future studies.
The Efficacy of Bracing in Nonoperative Care of Medial Femoral Condyle Osteochondritis Dissecans: A Study From the Research in Osteochondritis Dissecans of the Knee (ROCK) Study Group
Group, The ROCK, Nissen, Carl W. , Albright, Jay C. , Anderson, Christian N. , Busch, Michael T., Carey, James L. , Carlson, Cathy , Carsen, Sasha , Crepeau, Allison, Edmonds, Eric W. , Ellermann, Jutta , Ellis, Henry B. , Erickson, John B. , Godin, Jonathan , Ganley, Theodore J. , Grimm, Nathan L. , Heyworth, Benton E. , Po, James Hui Hoi, Kocher, Mininder S., Koehler, Ryan, Latz, Kevin, Loveland, Dustin M., Lyon, Roger M., Meenen, Norbert M., Milewski, Matthew D., Myer, Gregory D., Nelson, Bradley J., Nepple, Jeffrey, Nguyen, Jie C. , Paterno, Mark V. , Pennock, Andrew T. , Perkins, Crystal A. , Polousky, John D. , Riley, Pat, Saluan, Paul, Shea, Kevin G., Tompkins, Marc , Wall, Eric J. , Willimon, S. Clifton , Wright, Rick W. , Shea, Kevin G. , Edmonds, Eric W , Ellis, Henry B , Fabricant, Peter D , Ganley, Theodore J , Green, Daniel W , Heyworth, Benton E , Krych, Aaron J , Pace, J Lee , Pennock, Andrew T , Perkins, Crystal A , Tompkins, Marc A , Nissen, Carl , Busch, Michael T., Carlson, Cathy, Chambers, Henry G. , Godin, Jonathan, Hui, James Hoi Po, Kocher, Mininder Singh , Koehler, Ryan J. , Krych, Aaron J. , Lyon, Roger, Meenen, N. M., Milewski, Matthew D. , Myer, Gregory D. , Nelson, Bradley J. , Nepple, Jeffrey J. , Weiss, Jennifer M., Wilson, Philip L. , Kostyun, Regina O.

Mayo Clinic

The American Journal of Sports Medicine | April 15, 2026 | Volume: 54 | Issue: 6 | Pages: 1415-1422

10.1177/03635465261429407 | PMID 41981903 Get It

Background: Stable osteochondritis dissecans (OCD) lesions are primarily treated nonoperatively. Nonoperative treatment includes several recommendations, including the use of an unloader brace. However, little is known about the clinical effectiveness of unloader bracing and its influence on OCD healing, return to sports, and patient-reported outcomes (PROs). The purpose of this investigation was to evaluate the impact of unloader bracing on patients with stable medial femoral condyle (MFC) OCD lesions treated nonoperatively. Purpose: To investigate the influence of valgus unloader bracing on the success of treating stable MFC OCD with nonoperative treatment strategies. Study Design: Cohort study; Level of evidence, 2. Methods: The authors used a prospective cohort of patients receiving nonoperative care for stable MFC knee OCD lesions. The primary variable of interest was the efficacy of bracing. The primary outcomes were transition from nonoperative care to surgical intervention, return-to-play (RTP) clearance, and PROs. Bivariate testing was used to determine if there were differences between groups. Chi-square testing was used to determine if there were differences in rates of transition to surgery by group. The timing of the transition by each group was assessed using a Wilcoxon rank-sum test, given the nonparametric nature of the data. Kaplan-Meier survival analysis was used to calculate time at risk, incidence rate, and survival times for each group. Results: A total of 185 knees (bracing group: 123 [66.5%] knees; no-bracing group: 62 [33.5%] knees) were analyzed. Overall, 142 (76.8%) knees were successfully treated nonoperatively. Transition to surgery occurred in 43 (23.2%) knees. There were no differences in transition to surgery by groups, with no differences seen by group. Of the knees that did not transition to surgical care, 65 (71.4%) in the bracing group and 38 (74.5%) in the no-bracing group received RTP clearance ( P = .693). PRO scores were similar between the 2 groups at the time of RTP clearance. Conclusion: The inclusion of an unloader brace in the nonoperative treatment for stable MFC OCD lesions did not decrease the likelihood of patients undergoing surgical intervention or improve their PRO scores at the time of RTP clearance. Registration: NCT02771496 (ClinicalTrials.gov identifier).